Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A "Real-World", Randomized, Open-Label, Study on the Efficacy, Safety, and Tolerability of Tecarfarin (ATI-5923) a Novel Vitamin K Antagonist, Versus Warfarin in Subjects Requiring Chronic Anticoagulation

Trial Profile

A "Real-World", Randomized, Open-Label, Study on the Efficacy, Safety, and Tolerability of Tecarfarin (ATI-5923) a Novel Vitamin K Antagonist, Versus Warfarin in Subjects Requiring Chronic Anticoagulation

Status: Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 29 Jan 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tecarfarin (Primary) ; Warfarin
  • Indications Thromboembolism; Thrombosis
  • Focus Registrational; Therapeutic Use
  • Acronyms TACT
  • Sponsors Armetheon; Espero BioPharma; Espero Pharmaceuticals
  • Most Recent Events

    • 23 Jan 2018 Planned End Date changed from 1 Mar 2018 to 1 Jul 2019.
    • 23 Jan 2018 Planned primary completion date changed from 1 Mar 2018 to 30 Mar 2019.
    • 23 Jan 2018 Planned initiation date changed from 1 Dec 2016 to 1 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top